An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease | Zendy

Kodi S. Ravichandran | Zendy; Iram Zafar | Zendy; Abdullah Özkök | Zendy; Charles L. Edelstein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease

Author(s) -

Kodi S. Ravichandran,

Iram Zafar,

Abdullah Özkök,

Charles L. Edelstein

Publication year - 2014

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfu296

Subject(s) - pi3k/akt/mtor pathway , mtorc1 , medicine , everolimus , mtorc2 , polycystic kidney disease , sirolimus , kinase , discovery and development of mtor inhibitors , rptor , pharmacology , cancer research , disease , signal transduction , microbiology and biotechnology , biology

The mTOR pathway, which consists of mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), is activated in polycystic kidney disease (PKD) kidneys. Sirolimus and everolimus indirectly bind and inhibit mTORC1. A novel group of drugs, the mTOR kinase inhibitors, directly bind to mTOR kinase, thus inhibiting both mTORC1 and 2. The aim of the study was to determine the therapeutic effect of an mTOR kinase inhibitor, PP242, in the Han:SPRD rat (Cy/+) model of PKD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research